Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19
Our findings validate GRP78 as a target of OLN anti-cancer and anti-viral activities. These proof-of-principle studies support further investigation of OLN as a readily accessible compound to dually combat cancer and COVID-19.
Authors
- Roy Lau
- Crystal S. Conn (ORCID: https://orcid.org/0000-0003-3209-0445)
- Min A Yu (ORCID: https://orcid.org/0000-0002-3969-8720)
- Ze Liu (ORCID: https://orcid.org/0000-0002-1635-5573)
- Michael E. Doche (ORCID: https://orcid.org/0000-0003-2616-4065)
- Dat P. Ha (ORCID: https://orcid.org/0000-0002-2592-1223)
- Nektaria Maria Leli (ORCID: https://orcid.org/0000-0002-4662-9766)
- Woo‐Jin Shin (ORCID: https://orcid.org/0000-0002-2386-2717)
- Mariangela Russo (ORCID: https://orcid.org/0000-0003-4625-1449)
- Annalisa Lorenzato (ORCID: https://orcid.org/0000-0002-9324-2337)
- Shannon M. Mumenthaler (ORCID: https://orcid.org/0000-0003-2687-3769)
- Constantinos Koumenis (ORCID: https://orcid.org/0000-0001-5945-4726)
- Amy S. Lee (ORCID: https://orcid.org/0000-0002-0378-5443)
Institutions
- University of Southern California (US)
- Larry Ellison Foundation (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Cleveland Clinic Florida (US)
- USC Norris Comprehensive Cancer Center (US)
- University of Turin (IT)
- University of Pennsylvania (US)
Publication Details
- Journal
- Cell & Bioscience
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1186/s13578-024-01297-3
- Citations
- 9
- Primary Topic
- Endoplasmic Reticulum Stress and Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health